Clinical Trial Results: Positive data from Aurinia's clinical trials for Lupkynis (voclosporin) typically leads to increased investor confidence and a higher stock price. Conversely, negative or inconclusive results can cause a significant drop.

Regulatory Approvals: FDA or other regulatory agency approvals of Lupkynis for new indications or in different geographical regions usually drive the stock price upward, signaling expanded market potential.

Sales Performance: Strong sales figures for Lupkynis and revenue growth generally translate to higher stock value, reflecting the company's commercial success and profitability. Missed sales targets can negatively impact the price.

Competition: The presence of competing treatments for lupus nephritis and their market share can influence investor sentiment toward Aurinia. New entrants or superior efficacy of other drugs may lower AUPH's price.

Partnerships and Acquisitions: Potential partnerships, licensing agreements, or acquisition interest in Aurinia can create speculation and potentially boost the stock price. Failed deals can have the opposite effect.

Market Conditions: General market sentiment, macroeconomic factors, and industry trends in the pharmaceutical or biotechnology sectors can impact AUPH's stock price, irrespective of company-specific news.

Analyst Ratings: Upgrades from financial analysts often attract more investors and push the price higher, while downgrades may lead to selling pressure and a price decrease.

Financial Health: The company's cash position, debt levels, and overall financial stability play a role in investor confidence. A strong balance sheet can support a higher valuation.

Patent Protection: The strength and duration of Aurinia's patents for Lupkynis contribute to its competitive advantage. Patent expirations or challenges can negatively affect the stock price.

Management Team: Confidence in Aurinia's leadership and their ability to execute the company's strategy is important for investor sentiment. Changes in management can sometimes impact the stock price.